Citations

Clear

3942 citation(s) found for "To, Van".

Autoimmune Encephalitis Is the Most Common Treatment-Responsive Cause of Rapidly Progressive Dementia; a Large Dutch Prospective Cohort Study. (PL4.002)
Steenhoven, Robin van, Bastiaansen, Daniëlle, Vries, Juna de, Jong, Frank Jan de , Satyadev, Nihal , Smitt, Peter Sillevis, Day, Gregory, Day, Gregory S. , Day, Gregory S , Bastiaansen, Daniëlle, Brenner, J , Kerstens, Jeroen , Crijnen, Y S , Seelaar, Harro , Titulaer, Maarten J

Mayo Clinic

Neurology | April 7, 2025 | Volume: 104 | Issue: 7_Supplement_1 | Pages: No page available

10.1212/wnl.0000000000210982 Get It

Granulomatosis with polyangiitis presenting as strawberry gingivitis: methodologic aspects: comment on the article by Liu et al
Woude, Diane van der , Bajema, Ingeborg M., Specks, Ulrich , van der Woude, Diane , Specks, Ulrich

Mayo Clinic

Arthritis & Rheumatology | April 7, 2025 | Volume: 77 | Issue: 10 | Pages: 1454-1454

10.1002/art.43177 | PMID 40189926 Get It

Influence of body mass index on cardiovascular risk in rheumatoid arthritis varies across anti-citrullinated protein antibody status and biologic use
Karpouzas, George , González‐Gay, Miguel Á. , Corrales, Alfonso, Myasoedova, Elena , Rantapää‐Dahlqvist, Solbritt , Sfikakis, Petros P. , Dessein, PH, Pascual‐Ramos, Virginia , Contreras-Yáñez, Irazú , Galarza-Delgado, D. Á. , Riel, Piet Leonardus Cornelis Maria van, Patrick, D R, Løgstrup, Brian Bridal , Hauge, Ellen‐Margrethe , Karpouzas, George Athanasios , Dessein, Patrick , Pascual-Ramos, Virginia , Colunga-Pedraza, Iris J , Galarza-Delgado, Dionicio Angel , Semb, Anne Grete , Misra, Durga Prasanna , Gonzalez-Gay, Miguel A , Myasoedova, Elena , Rantapää-Dahlqvist, Solbritt , Hitchon, Carol , Colunga-Pedraza, I. J. , Azpiri-Lopez, Jose Ramon , Semb, Anne Grete , Riel, Piet L. C. M. van , Misra, Durga Prasanna , Kitas, George D. , Ormseth, Sarah R.

Mayo Clinic

RMD Open | April 5, 2025 | Volume: 11 | Issue: 2 | Pages: e005464

10.1136/rmdopen-2025-005464 | PMID 40187772 Get It

Objectives The impact of body mass index (BMI) on cardiovascular risk in rheumatoid arthritis (RA) is unclear. RA characteristics may influence the association between BMI and risk. Disease activity, which predicts cardiovascular risk, is associated with obesity only among anticitrullinated antibody (ACPA)-positive patients. Biologics alter body composition and mitigate cardiovascular risk in RA. We explored the association of BMI with cardiovascular risk and whether this varied across ACPA status and biologic use. Methods We evaluated 3982 patients from an international observational cohort. Outcomes included (a) first major adverse cardiovascular event (MACE) encompassing myocardial infarction, stroke or cardiovascular death; and (b) all events comprising MACE, angina, revascularisation, transient ischaemic attack, peripheral arterial disease and heart failure. Multivariable Cox models stratified by centre risk evaluated the impact of BMI, ACPA, biologics and their two- and three-way interactions on outcomes. Results We recorded 192 MACE and 319 total events. No main effects of BMI, ACPA or biologics were observed. A three-way interaction between them on MACE (p-interaction<0.001) and all events (p-interaction=0.028) was noted. Among ACPA negative patients, BMI was inversely associated with MACE (HR 0.38 (95% CI 0.25 to 0.57)) and all events (HR 0.67 (0.49 to 0.92)) in biologic users but not non-users (p-for-interaction <0.001 and 0.012). Among ACPA-positive patients, BMI was associated with MACE (HR 1.04 [1.01–1.07]) and all events (HR 1.03 (1.00 to 1.06)) independently of biologic use. Conclusions BMI is inversely associated with cardiovascular risk only among ACPA-negative biologic users. In contrast, BMI is associated with cardiovascular risk in ACPA-positive patients independently of biologic use.
MHC class II-mediated spontaneous rejection of breast carcinomas expressing model neoantigens
Jenkins, James W. , Peña, Alvaro, Castro, Sarah A, Hansen, Michael J. , Keulen, Virginia P. Van , Foster, Sean T, Rios-Cruz, Pablo E, Yakubov, Joshua, Hinson, Destin T , Olivier, S., Felts, Sara J. , Johnson, Aaron J. , Pease, Larry R. , Jenkins, James William , Olivier, Samuel M, Pease, Larry R , Foster, Sean T, Olivier, Samuel M, Pavelko, Kevin D. , Johnson, Aaron J.

Mayo Clinic

Journal for ImmunoTherapy of Cancer | April 5, 2025 | Volume: 13 | Issue: 4 | Pages: e010434

10.1136/jitc-2024-010434 | PMID 40187751 Get It

Background Cancers persist despite expression of immunogenic neoantigens and ongoing antitumor immune responses. While some occult tumors likely are cleared by effective antitumor immune responses, the targeted antigens are not easily identifiable as those tumors spontaneously disappear. Methods We used mouse models with a defined antigenic protein mimicking tumor-specific neoantigens to address the nature of these spontaneous anti-tumor immune responses. Results BALB/c (H-2d ) mice challenged with BALB/c breast tumors expressing the rat-erbB2 oncoprotein succumb to their tumors despite ongoing immune responses targeting tumor-specific model antigens. Meanwhile, congenic BALB.B (H-2b ) and H-2d/H-2b F1 hybrid mice spontaneously eliminate genetically matched tumors in a major histocompatibility complex (MHC)-II dependent manner. Adoptive transfer and immune cell depletion strategies revealed CD4+ T cells and CD20+ B cells are crucial mediators of the protective response in H-2b mice. Furthermore, passive transfer of immune serum from mice rejecting their tumors confers resistance in tumor antigen-tolerant animals with an inversely proportional relationship between tumor outgrowth and the amount of rat-erbB2 specific antibody present in tumor-bearing mice. Introduction of the rat-erb2 ectodomain into other H-2b tumor models also promotes their spontaneous tumor rejection. Notably, the tumor microenvironments differ in rat-erbB2+ tumor-bearing BALB.B and BALB/c mice at the time of fate decision in the models reflecting the differences between effective and ineffective tumor immune responses. Conclusions We find that the effective antitumor immunity targeting neoantigens in these breast cancer models is determined by MHC-II-restricted presentation of optimal cancer-associated antigens. These responses are dependent on CD4+ T cells, B cells, and antigen-specific antibodies.
Patient-Reported Quality-of-Life Outcome Measure After Parotidectomy
Lohse, Christine M. , Yost, Kathleen J. , Tuchscherer, Amy M., Martin, Eliot J., Semann, Heidi, Tasche, Kendall K. , Abel, Kathryn M. Van , Moore, Eric J. , Calcano, Gabriela A. , Van Abel, Kathryn M , Yin, Linda X. , Tuchscherer, Amy M., Price, Daniel L.

Mayo Clinic

JAMA Otolaryngology–Head & Neck Surgery | April 4, 2025 | Volume: 151 | Issue: 5 | Pages: 441

10.1001/jamaoto.2024.5253 | PMID 40178828 Get It

ImportanceThere is a lack of reliable, patient-reported quality-of-life (QOL) instruments to address the multidimensional nature of patient-centered outcomes for patients undergoing parotidectomy. The Parotidectomy Quality of Life Index is a new 35-item validated patient-reported outcome instrument specific to recovery after parotidectomy.ObjectiveTo establish and validate a comprehensive English-language patient-reported QOL instrument specific to parotidectomy.Design, Setting, and ParticipantsThis survey study was conducted in 2 phases: first, in a single-institution cohort (October 12, 2021, to March 7, 2022), and second, as an anonymous web-based survey enrolled via printed promotional brochures and social media platforms (March 13 to July 31, 2023). Inclusion criteria were age at least 18 years and parotidectomy within the last year. For test-retest reliability, a subset of phase II participants volunteered to answer the survey a second time within 2 weeks. Data were analyzed from March 8, 2022, to November 3, 2023.Main Outcomes and MeasuresItem rankings from phase I participants were used to narrow the original 61-item survey down to 45 items in the phase II survey. To assess construct validity, an exploratory factor analysis was performed. Cronbach α and pairwise Pearson correlation coefficients were used to measure internal consistency, reliability, and redundancy. Test-retest reliability was evaluated using intraclass correlation coefficients.ResultsPhase I enrolled 38 individuals, of whom 30 completed the survey (15 women [60%]; 21 participants [84%] aged &amp;gt;40 years). Phase II enrolled 342 participants, of whom 317 completed the survey (305 women [89%]; 284 participants [83%] aged &amp;gt;40 years). A total of 42 items across 7 domains were selected based on exploratory factor analysis. After Cronbach α and pairwise correlation analysis, 33 items across 6 multi-item domains and 2 standalone items were incorporated into the final QOL instrument. Cronbach αs for each of the final 6 domains were at least 0.77, suggesting excellent internal validity. Pairwise correlations did not show strong correlations (ie, none ≥0.80), suggesting minimal redundancy between domains. Younger age was significantly associated with a lower global score. Participants with malignant tumors scored lower on 4 of the 6 multi-item domains. Test-retest reliability coefficients for the domains ranged from 0.82 to 0.93, indicating very good reproducibility over a 2-week interval.Conclusions and RelevanceThese findings suggest the Parotidectomy Quality of Life Index demonstrated excellent internal validity and test-retest reliability. With further external validation, this instrument may provide opportunity for quality improvement in clinical practice and has potential as a key patient-reported outcome in future parotidectomy clinical trials.
Intracranial stimulation for pediatric refractory epilepsy: A single institutional experience using evolving therapies
Singh, Rohin , Bauman, Megan M. J. , Islam, Karimul , Kerezoudis, Panagiotis , Grewal, Sanjeet S. , Parker, Jonathon J. , Gompel, Jamie J. Van , Miller, Kai J. , Lundstrom, Brian N. , Starnes, Keith , Van Gompel, Jamie J , Grewal, Sanjeet , Lundstrom, Brian Nils , Bauman, Megan , Starnes, Donnie Keith , Singh, Rohin , Islam, Karimul

Mayo Clinic

Epilepsia Open | April 2, 2025 | Volume: 10 | Issue: 3 | Pages: 694-704

10.1002/epi4.70006 | PMID 40167570 Get It

AbstractObjectiveNeuromodulation for pediatric refractory epilepsy (PRE) is preferred when the seizure onset zone is not amenable to surgical resection, due to multifocal onset or involvement of eloquent cortex. Given its rapidly evolving landscape, we describe our institutional experience with neurostimulation therapies including deep brain stimulation (DBS) of the anterior nucleus (DBS‐ANT), the centromedian nucleus (DBS‐CM), responsive neurostimulation (RNS), and chronic subthreshold stimulation (CSS) to treat PRE.MethodsA retrospective chart review was conducted to identify pediatric patients (≤18 years of age) who presented to our institution with PRE. Patients were included who had at least 1 year of follow‐up after neurostimulation was started. Patients with ≥50% seizure frequency reduction at last follow‐up compared to baseline were classified as responders.ResultsA total of 35 patients (21 females) were included in the series. Nine patients underwent DBS‐ANT, 9 underwent DBS‐CM (+ ANT in 7 patients), 5 underwent RNS, and 12 underwent CSS. The median age at seizure onset and surgery was 8 and 16 years, respectively. Structural lesions were the most common etiology of epilepsy (54%). Eighteen patients had prior interventions and 13 received invasive EEG. Post‐operative complications following neurostimulation implantation were noted in three patients (9%). However, no permanent deficits were noted. Median follow‐up time was 46 months (range 13–162 months). Twenty‐three patients (59%) were responders (3/9 DBS‐ANT; 7/9 DBS‐CM; 4/5 RNS; 9/12 CSS). Further, median seizure reduction was 25% (DBS‐ANT), 89% (DBS‐CM), 87% (RNS), and 88% (CSS) across the cohort. Six patients (17%) had improved subjective neurocognitive outcomes while the other 29 had stable neurocognitive outcomes.SignificanceDBS, RNS, and CSS are safe and effective options for PRE. An understanding of treatment approaches can optimize results by tailoring therapy to individual patients.Plain Language SummaryThis study investigates the use of various neurostimulation therapies for treating pediatric refractory epilepsy (PRE) including deep brain stimulation (DBS), responsive neurostimulation (RNS), and chronic subthreshold stimulation (CSS). Overall, neuromodulation was found to be effective in reducing seizures in most patients, with 59% of patients showing at least a 50% reduction in seizure frequency. Additionally, the treatments were generally safe, with few complications and no instances of permanent deficits.
The Impact of Hydrostatic Pressure on Fractional Flow Reserve in Saphenous Vein Grafts
Hoek, Roel , Porouchani, Sina , Winter, Ruben W. de , Somsen, Yvemarie , Diemen, Pepijn A. van , Wilgenhof, Adriaan , Verouden, Niels , Danad, Ibrahim , Nap, A , Knaapen, Paul , de Winter, Ruben W , Somsen, Yvemarie B O , van Diemen, Pepijn A , Wilgenhof, Adriaan , Planken, Nils R, Knaapen, Paul , Jukema, Ruurt , Twisk, Jos W. R. , Hartog, Alexander W. den , Planken, R. Nils , Nap, Alexander

Mayo Clinic

Catheterization and Cardiovascular Interventions | April 1, 2025 | Volume: 106 | Issue: 1 | Pages: 80-89

10.1002/ccd.31509 | PMID 40165396 Get It

ABSTRACT Background The relationship between height differences related to graft anatomy and physiological pressure indices in coronary bypass grafts has not been studied. We sought to study the impact of hydrostatic pressure on fractional flow reserve (FFR) in saphenous vein grafts (SVGs). Methods Included were 66 symptomatic patients (76 SVGs) with prior coronary artery bypass grafting who underwent coronary computed tomography angiography (CCTA) preceding invasive coronary angiography with FFR interrogation of ≥ 1 SVGs. The graft course and height excursion were reconstructed based on CCTA images. The impact of hydrostatic pressure on FFR (corrected FFR) was calculated by adding or subtracting 0.077 mmHg to the distal coronary pressure for every millimeter height difference in a supine position between the SVG ostium and the pressure wire tip position. Results The height difference (mm) between the SVG ostium and pressure wire tip position was largest for single SVGs to the circumflex artery (Cx; −55.1 ± 17.0), followed by sequential SVGs to the Cx (−51.8 ± 17.3) and the right coronary artery (RCA; −36.7 ± 21.6). The correlation between height difference and uncorrected FFR was −0.59 ( p < 0.001). Corrected FFR was lower as compared to uncorrected FFR in the overall cohort (0.86 ± 0.17 vs. 0.88 ± 0.18), in single SVGs to Cx (0.85 ± 0.17 vs. 0.90 ± 0.18), and in sequential SVGs to Cx (0.92 ± 0.14 vs. 0.96 ± 0.15) and RCA (0.82 ± 0.17 vs. 0.85 ± 0.21) ( p < 0.001 for all). Conclusions Hydrostatic pressure related to height differences along the course anatomy of SVGs can impact FFR measurements, with corrected FFR being significantly lower in SVGs to the Cx and sequential SVGs to the RCA.
Selective Elimination of Breast Surgery for Invasive Breast Cancer
Kuerer, Henry M. , Valero, V, Krishnamurthy, Savitri, Diego, Emilia J. , Lin, Heather , Shen, Yu , Mitchell, Melissa P. , Yang, Wei , Group, Exceptional Responders Study, Moseley, Tanya W. , Leung, Jessica WT, Huang, Monica L. , Parra, Raquel FD van la, Teshome, Mediget , Hwang, Rosa F. , Miggins, Makesha, Piotrowski, Matthew J., Refinetti, Ana P, Ehlers, Richard A., Mouabbi, Jason , Colen, Jessica Suarez, Loveland‐Jones, Catherine, Lesnikowski, Beth Ann, Samiian, Laila, Chong, Clayton, Black, Dalliah M. , Desyder, Sarah M, Nguyen, Tuyen , Smith, Benjamin D. , Krishnamurthy, Savitri , Johnson, Helen Margaret , Lucci, Anthony , Shaitelman, Simona Flora , Boughey, Judy C. , White, Richard L., Hunt, Kelly K. , Rauch, Gaiane M. , Group, Exceptional Responders Study, Candelaria, Rosalind P. , Adrada, Beatriz E. , Arribas, Elsa , Ramirez, David Luis , Sun, Susie X.

Mayo Clinic

JAMA Oncology | March 28, 2025 | Volume: 11 | Issue: 5 | Pages: 529

10.1001/jamaoncol.2025.0207 | PMID 40152443 Get It

Importance Neoadjuvant systemic therapy (NST) has been associated with pathologic complete response (pCR) in up to 60% of breast cancers (BCs). The findings of this trial question the necessity of surgery. Objective To report preplanned 5-year efficacy outcomes evaluating radiotherapy alone without breast surgery in patients selected with image-guided vacuum assisted biopsy (VAB). Design, Setting, and Participants This single-arm, prospective, phase 2 nonrandomized clinical trial was conducted at 7 US medical centers and included women 40 years or older with cT1-2N0-1M0 ERBB2 -positive (formerly HER2 -positive) or triple-negative invasive BC who showed residual breast lesions after NST of less than 2 cm on imaging. Enrollment was from March 6, 2017, to November 9, 2021. Data analysis was from October to December 2024. Intervention Image-guided VAB of the tumor bed (9G with a minimum of 12 cores) was performed after standard NST. Patients with clinically node-negative disease at diagnosis and no residual cancer in the breast on post-NST VAB underwent whole-breast radiotherapy with a boost without breast or axillary surgery. Patients with initial documented nodal disease and a breast pCR on VAB underwent targeted axillary dissection, while those with residual cancer when undergoing VAB had standard breast and axillary surgery. Patients were monitored with physical examinations and mammography every 6 months. Main Outcome Measures The primary outcome was ipsilateral breast tumor recurrence. Results Fifty patients (median [IQR] age, 62 [55-77] years) were enrolled and underwent post-NST VAB. Twenty-nine (58%) and 21 (42%) patients had ERBB2 -positive and triple-negative invasive BC, respectively. Breast pCR on VAB was identified in 31 patients (62%; 95% CI, 47.2%-75.34%), and axillary pCR was identified among all 8 patients with initial nodal metastases and breast pCR on VAB who underwent targeted axillary dissection. At a median follow-up of 55.4 (IQR, 44.0-63.5) months, the ipsilateral breast tumor recurrence rate was 0%, and disease-free and overall survival rates were 100% for patients without breast surgery. Conclusions and Relevance The results of this nonrandomized clinical trial that reported preplanned 5-year outcomes suggest that omission of breast surgery in select patients after NST may be feasible, with no recurrences seen. More confirmatory studies are necessary before this new approach alters surgical practice. Trial Registration ClinicalTrials.gov Identifier: NCT02945579
Prognostic Implications of Functional Tricuspid Regurgitation in Asymptomatic Degenerative Mitral Regurgitation
Tribouilloy, Christophe , Bohbot, Yohann, Benfari, Giovanni , Bax, J. J., Antoine, Clémence , Ruşinaru, Dan, Wijngaarden, Aniek Van, Roussel, J, Thapa, Prabin , Hector, Michelena, Enriquez-Sarano, Maurice , Benfari, Giovanni , Essayagh, Benjamin , Tourneau, Thierry Le , Topilsky, Yan , Grigioni, Francesco , Marsan, Nina Ajmone , Hochstadt, Aviram , Hector, Michelena, Enriquez‐Sarano, Maurice

Mayo Clinic

ESC Heart Failure | March 23, 2025 | Volume: 12 | Issue: 4 | Pages: 2591-2596

10.1002/ehf2.15278 | PMID 40122615 Get It

Abstract Aims Functional tricuspid regurgitation (FTR) associated with degenerative mitral regurgitation (DMR) accentuates the severity of heart failure and is a marker of poor prognosis. Little is known about FTR associated with asymptomatic DMR. Methods and results The study included 1249 asymptomatic patients with moderate or severe DMR from the Mitral Regurgitation International Database-Quantitative (MIDA-Q) registry (mean age 64 ± 15 years, 25% female). Despite the asymptomatic status, absent/trivial FTR was noted in only 42%, mild in 34.5%, moderate in 11%, and severe FTR in 12.5%. Patients with higher FTR grades were older and more often female and had higher EuroScore II, larger left atrial volumes, and more atrial fibrillation (all P &lt; 0.05). Patients with moderate or severe FTR had comparable 5-year survival (64 ± 4% and 65 ± 4%) and lower than patients with no/trivial FTR(96 ± 1%, P &lt; 0.001). After adjustment for key prognostic factors, including age, left ventricular dilatation and dysfunction, DMR severity, left atrial dilatation, and pulmonary hypertension, ≥moderate FTR remained a strong predictor of mortality (HR = 2.08 [1.17–3.72], P = 0.013). Sensitivity analysis showed stable impact of ≥moderate FTR among patients with/without pulmonary hypertension, in women and men and for any other subset. For patients who underwent mitral valve surgery, post-operative survival rates were similar between those with no/trivial FTR and those with ≥moderate or severe FTR (P = 0.76), suggesting that surgery could reduce the excess mortality related to preoperative FTR. Conclusions Among asymptomatic patients with significant DMR, ≥moderate FTR is frequent and independently associated with higher mortality, independently of traditional guideline-based risk factors. These findings suggest that ≥moderate FTR should lead to consideration of early mitral surgery to improve outcomes.
Management of patients with small pancreatic neuroendocrine tumors from a biomarker and surgical perspective
Verschuur, Anna Vera D , Chen, Lin , Dijkum, Els J. Nieveen van, Luchini, Claudio, Halfdanarson, Thorvardur R, Hong, Seung‐Mo , Heaphy, Christopher M. , Hálfdánarson, Þorvarður R. , Halfdanarson, Thorvardur R , Heaphy, Christopher M , Chen, Lin , Dijkum, Els J.�M. Nieveen van , Luchini, Claudio , Singhi, Aatur Dilip , Brosens, Lodewijk A.A.

Mayo Clinic

Endocrine-Related Cancer | March 21, 2025 | Volume: 32 | Issue: 5 | Pages: No page available

10.1530/erc-24-0305 | PMID 40117346 Get It

Abstract Pancreatic neuroendocrine tumors (PanNETs) have an age-adjusted incidence of 1.5 per 100,000 people, with a notable rise in the incidence of small (≤2 cm) non-functional PanNETs (NF-PanNETs) in recent decades. While surgery is traditionally the preferred treatment for localized NF-PanNETs, active surveillance is now an accepted management strategy for tumors smaller than 2 cm due to their relatively benign behavior. However, this approach has not yet been fully integrated into routine clinical practice. There is considerable histopathological heterogeneity observed in NF-PanNETs, which results in significant variability in clinical presentation, behavior and treatment outcomes. Hence, tumor size alone does not provide sufficient certainty regarding a benign clinical course for decision-making. Although studies advocate for incorporating WHO grade into clinical prognostic assessments, this marker also has limitations. Several established tissue-based markers, such as ATRX and DAXX alterations, alternative lengthening of telomeres, and copy number variations, can be used for PanNET subtyping and correlate with metastatic risk. Combining these markers with traditional histopathological parameters may yield a more comprehensive and accurate prognostic assessment. This review discusses the advantages and limitations of current prognostication methods for small NF-PanNETs and highlights recently established prognostic markers, along with the requirements for their implementation into routine clinical practice. It also proposes practical solutions to address the challenges associated with the immediate integration of these biomarkers into routine care.